These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 38771066)
1. In Vivo Assessment of Astrocyte Reactivity in Patients with Progressive Supranuclear Palsy. Hirata K; Matsuoka K; Tagai K; Endo H; Tatebe H; Ono M; Kokubo N; Kataoka Y; Oyama A; Shinotoh H; Takahata K; Obata T; Dehghani M; Near J; Kawamura K; Zhang MR; Shimada H; Shimizu H; Kakita A; Yokota T; Tokuda T; Higuchi M; Takado Y Ann Neurol; 2024 Aug; 96(2):247-261. PubMed ID: 38771066 [TBL] [Abstract][Full Text] [Related]
2. Altered Brain Energy Metabolism Related to Astrocytes in Alzheimer's Disease. Hirata K; Matsuoka K; Tagai K; Endo H; Tatebe H; Ono M; Kokubo N; Oyama A; Shinotoh H; Takahata K; Obata T; Dehghani M; Near J; Kawamura K; Zhang MR; Shimada H; Yokota T; Tokuda T; Higuchi M; Takado Y Ann Neurol; 2023 Sep; ():. PubMed ID: 37703428 [TBL] [Abstract][Full Text] [Related]
3. Tau accumulation in astrocytes in progressive supranuclear palsy is a degenerative rather than a reactive process. Togo T; Dickson DW Acta Neuropathol; 2002 Oct; 104(4):398-402. PubMed ID: 12200627 [TBL] [Abstract][Full Text] [Related]
10. Delineation of early changes in cases with progressive supranuclear palsy-like pathology. Astrocytes in striatum are primary targets of tau phosphorylation and GFAP oxidation. Santpere G; Ferrer I Brain Pathol; 2009 Apr; 19(2):177-87. PubMed ID: 18462470 [TBL] [Abstract][Full Text] [Related]
11. Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. Brendel M; Barthel H; van Eimeren T; Marek K; Beyer L; Song M; Palleis C; Gehmeyr M; Fietzek U; Respondek G; Sauerbeck J; Nitschmann A; Zach C; Hammes J; Barbe MT; Onur O; Jessen F; Saur D; Schroeter ML; Rumpf JJ; Rullmann M; Schildan A; Patt M; Neumaier B; Barret O; Madonia J; Russell DS; Stephens A; Roeber S; Herms J; Bötzel K; Classen J; Bartenstein P; Villemagne V; Levin J; Höglinger GU; Drzezga A; Seibyl J; Sabri O JAMA Neurol; 2020 Nov; 77(11):1408-1419. PubMed ID: 33165511 [TBL] [Abstract][Full Text] [Related]
12. Case report of a patient with unclassified tauopathy with molecular and neuropathological features of both progressive supranuclear palsy and corticobasal degeneration. Koga S; Metrick MA; Golbe LI; Santambrogio A; Kim M; Soto-Beasley AI; Walton RL; Baker MC; De Castro CF; DeTure M; Russell D; Navia BA; Sandiego C; Ross OA; Vendruscolo M; Caughey B; Dickson DW Acta Neuropathol Commun; 2023 Jun; 11(1):88. PubMed ID: 37264457 [TBL] [Abstract][Full Text] [Related]
13. Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy. Cope TE; Rittman T; Borchert RJ; Jones PS; Vatansever D; Allinson K; Passamonti L; Vazquez Rodriguez P; Bevan-Jones WR; O'Brien JT; Rowe JB Brain; 2018 Feb; 141(2):550-567. PubMed ID: 29293892 [TBL] [Abstract][Full Text] [Related]
14. Midcingulate involvement in progressive supranuclear palsy and tau positive frontotemporal dementia. Chiu WZ; Papma JM; de Koning I; Donker Kaat L; Seelaar H; Reijs AE; Valkema R; Hasan D; Boon AJ; van Swieten JC J Neurol Neurosurg Psychiatry; 2012 Sep; 83(9):910-5. PubMed ID: 22733085 [TBL] [Abstract][Full Text] [Related]
15. Multireceptor fingerprints in progressive supranuclear palsy. Chiu WZ; Donker Kaat L; Boon AJW; Kamphorst W; Schleicher A; Zilles K; van Swieten JC; Palomero-Gallagher N Alzheimers Res Ther; 2017 Apr; 9(1):28. PubMed ID: 28412965 [TBL] [Abstract][Full Text] [Related]
17. Two pathways differentially linking tau depositions, oxidative stress, and neuronal loss to apathetic phenotypes in progressive supranuclear palsy. Matsuoka K; Takado Y; Tagai K; Kubota M; Sano Y; Takahata K; Ono M; Seki C; Matsumoto H; Endo H; Shinotoh H; Sahara Y; Obata T; Near J; Kawamura K; Zhang MR; Suhara T; Shimada H; Higuchi M J Neurol Sci; 2023 Jan; 444():120514. PubMed ID: 36473346 [TBL] [Abstract][Full Text] [Related]
18. In vivo evidence for decreased scyllo-inositol levels in the supplementary motor area of patients with Progressive Supranuclear Palsy: A proton MR spectroscopy study. Barbagallo G; Morelli M; Quattrone A; Chiriaco C; Vaccaro MG; Gullà D; Rocca F; Caracciolo M; Novellino F; Sarica A; Arabia G; Sabatini U; Quattrone A Parkinsonism Relat Disord; 2019 May; 62():185-191. PubMed ID: 30558837 [TBL] [Abstract][Full Text] [Related]
19. Neuroinflammation predicts disease progression in progressive supranuclear palsy. Malpetti M; Passamonti L; Jones PS; Street D; Rittman T; Fryer TD; Hong YT; Vàsquez Rodriguez P; Bevan-Jones WR; Aigbirhio FI; O'Brien JT; Rowe JB J Neurol Neurosurg Psychiatry; 2021 Jul; 92(7):769-775. PubMed ID: 33731439 [TBL] [Abstract][Full Text] [Related]
20. 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. Passamonti L; Vázquez Rodríguez P; Hong YT; Allinson KS; Williamson D; Borchert RJ; Sami S; Cope TE; Bevan-Jones WR; Jones PS; Arnold R; Surendranathan A; Mak E; Su L; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB Brain; 2017 Mar; 140(3):781-791. PubMed ID: 28122879 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]